Digest Network Come funziona
Network
/
Società
La
Non verificato

Latus Bio, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza

8 comunicati stampa

Guarda tutti i comunicati
16/06/2026
Mercato del lavoro
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Latus Bio Appoints Bethany Mancilla as Chief Business Officer
Fonte
Latus Bio, Inc.
Emittente
Business Wire
1.00
0
04/05/2026
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Latus Bio Announces $97 Million Series A Financing to Expand the Reach of Gene Therapy to Larger Populations
Fonte
Latus Bio, Inc.
Emittente
Business Wire
1.00
0
28/04/2026
Eventi
Fiere
Industria
Scienza
Biotecnologia
Sanità
Salute
Medicina - Varie
Latus Bio to Present New Data at ASGCT 2026 Supporting Investigational Gene Therapy Approaches for Huntington’s Disease and CLN2 Disease
Fonte
Latus Bio, Inc.
Emittente
Business Wire
1.00
0
02/12/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Infanzia
Vetrine/Shopping
Latus Bio Announces IND Clearance of LTS-101 for CLN2 Disease and Receipt of Fast Track, Orphan Drug, and Rare Pediatric Disease Designations
Fonte
Latus Bio, Inc.
Emittente
Business Wire
1.00
0
03/11/2025
Scienza
Biotecnologia
Salute
Tecnica
Mercato del lavoro
Industria
Latus Bio Launches AI/ML Strategy to Transform AAV Gene Therapy, Adds Two Leading Experts in Peptide and Protein Modeling to Scientific Advisory Board
Fonte
Latus Bio, Inc.
Emittente
Business Wire
1.00
0
20/05/2025
Industria
Scienza
Biotecnologia
Sanità
Salute
Farmaceutica
Latus Bio Announces Publication of Breakthrough Research on Novel AAV Capsid Variant for Huntington’s and Parkinson’s Disease Gene Therapy
Fonte
Latus Bio, Inc.
Emittente
Business Wire
1.00
0
14/05/2025
Industria
Salute
Biotecnologia
Scienza
Latus Bio Unveils AAV-Ep+ Capsid Variant Capable of Unprecedented Protein Production in the Brain
Fonte
Latus Bio, Inc.
Emittente
Business Wire
1.00
0
24/02/2025
Eventi
Fiere
Industria
Salute
Biotecnologia
Sanità
Farmaceutica
Latus Bio Announces Data Presentations in Support of its Preclinical Huntington’s Disease Gene Therapy Program
Fonte
Latus Bio, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0